The expanded indication prechemotherapy would give Zytiga an advantage as it competes with the likes of Sanofi's Jevtana (cabazitaxel), which had sales of around $50m in the first quarter of 2012 and is currently indicated for second- and third-line use in mCRPC. Zytiga sales for the same quarter were 4 fold higher at $ 200M reflecting the oncologists preferred use of Zytiga.
Zytiga is also being tested in a phase III trial as a first-line treatment for prostate cancer.
No comments:
Post a Comment